SYNARC to Attend AD/PD 2013 Conference

Newark, CA – February 28, 2013 – SYNARC, the world's leading provider of medical imaging services for the pharmaceutical, biotechnology, and medical device industries, announced today that Dr. Joyce Suhy will be attending The 11th International Conference on Alzheimer's and Parkinson's Diseases in Florence, Italy, March 5th - 10th. At the meeting, Dr. Suhy will be giving key presentations. Among them is one poster and one oral presentation:

Date: Thursday March 7, 2013
Symposium 16 Clinical Trial Design
Amyloid PET Screening for Enrollment into AD Clinical Trials: Initial Experience in a Phase 1b Clinical Trial
Time: 12:50 - 13:10

Date: Thursday March 7, 2013
"Hippocampus Atrophy in Early Alzheimer's Disease Quantified Using Non-rigid Registration with Cube Propagation"
Time: 09:00 - 17:00
“Utilization of a Protease Generated Fragment of Tau as a Biomarker of Alzheimer's Disease”

Author(s): K. Henriksen, M.G. Sørensen, Y. Wang, K. Duffin, R.A. Dean, J.T. Pedersen, J. Suhy, M.A. Karsdal
Institute(s): Neurodegenerative Diseases, Nordic Bioscience A/S, Herlev, Denmark, Nordic Bioscience Beijing, Beijing, China, Eli Lilly & Company, Indianapolis, IN, USA, H Lundbeck, Copenhagen, Denmark, Synarc, Inc., Newark, CA, US

The International Conference on Alzheimer's and Parkinson's Diseases represents international medical and scientific professionals worldwide. The meeting is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's, and other related neurodegenerative diseases. The AD/PD Conference is geared towards examining the similarities and differences of distinct neurodegenerative diseases for the purposes of recognizing the disease mechanisms, prevention, and therapy

About SYNARC
SYNARC has more experience in conducting trials in Alzheimer's disease (AD) than any other central imaging provider. We have supported more than 65 clinical trials in the neurology therapeutic area that included central imaging in Phases I, II, III and IV. These include eligibility and efficacy assessments for both MRI and PET endpoints as well as safety reading and reporting services of amyloid related imaging abnormalities (ARIA – E and H). Furthermore, SYNARC has been an active member of the Private Partner Scientific Board (PPSB) of the US Alzheimer's Disease Neuroimaging Initiative (ADNI) since its inception. Our scientists have led the design and scientific oversight of neurology clinical trials at SYNARC for over a decade; they also provide technical training to the SYNARC project teams and participate on several expert panels to advance the use of imaging in clinical trials. For more information, please visit www.synarc.com.